Marco Boscaro

Marco Boscaro

Auto-generated profile, based on publicly available information

Marco Boscaro

Endocrinology Unit, Department of Medicine, Hospital-University , Padova 35128

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in JACC
Verified
Journal Article
Closed access
GRGian Paolo Rossi
Gian Paolo Rossi
GBGiampaolo Bernini
Giampaolo Bernini
CCChiara Caliumi
Chiara Caliumi
GDGiovambattista Desideri
Giovambattista Desideri
BFBruno Fabris
Bruno Fabris
FMFranco Mantero
Franco Mantero

1 December 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GAG. Arnaldi
G. Arnaldi
AAA. Angeli
A. Angeli
AAA. B. Atkinson
A. B. Atkinson
XBX. Bertagna
X. Bertagna
FCF. Cavagnini
F. Cavagnini
MBM. Boscaro
M. Boscaro
In October 2002, a workshop was held in Ancona, Italy, to reach a Consensus on the management of Cushing’s syndrome. The workshop was organized by the University of Ancona and sponsored by the Pituitary Society, the European Neuroendocrine Association, and the Italian Society of Endocrinology. Invited international participants included almost 50 leading endocrinologists with specific expertise in the management of Cushing’s syndrome. The consensus statement on diagnostic criteria and the diagnosis and treatment of complications of this syndrome reached at the workshop is hereby summarized.

1 July 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
BBB. M. K. Biller
B. M. K. Biller
AGA. B. Grossman
A. B. Grossman
PSP. M. Stewart
P. M. Stewart
SMS. Melmed
S. Melmed
XBX. Bertagna
X. Bertagna
MBM. Boscaro
M. Boscaro
Objective: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing’s syndrome, because there is no recent consensus on the management of this rare disorder. Participants: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing’s syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing’s disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing’s disease, and 5) management of ectopic ACTH syndrome, Nelson’s syndrome, and special patient populations. Evidence: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. Consensus Process: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. Conclusions: ACTH-dependent Cushing’s syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing’s syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing’s disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing’s syndrome, early diagnosis and prompt therapy are warranted.

1 October 2003 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
Luisa BarzonLuisa Barzon
Luisa Barzon
NSN Sonino
N Sonino
FFFrancesco Fallo
Francesco Fallo
GPG Palu
G Palu
MBM Boscaro
M Boscaro
Clinically silent adrenal masses discovered by imaging studies performed for unrelated reasons, i.e. adrenal incidentalomas, have become a rather common finding in clinical practice. However, only limited studies of incidence, prevalence, and natural history of adrenal incidentalomas are available. A comprehensive review of the literature shows the prevalence of adrenal incidentalomas to be 2.3% at autopsy and 0.5-2% at abdominal computed tomography scan. Most lesions are adrenocortical adenomas at histology, whereas the prevalence of adrenocortical carcinomas is relatively low. The risk of malignancy over time for masses defined as benign at diagnosis is estimated at about 1/1000, even though 5-25% of masses increase in size during follow-up. Hyperfunction develops in about 1.7% of cases and the risk is higher in patients with lesions larger than 3 cm. Cortisol hypersecretion is the most likely disorder that may ensue, and it remains subclinical in about two-thirds of cases. The lack of controlled studies precludes making specific management recommendations. Large perspective controlled studies to define the epidemiology, natural history, and possible associated morbidity of adrenal incidentalomas and their impact on the quality of life of patients are needed.

Verified
Journal Article
Open access
PDF file
DADecio Armanini
Decio Armanini
MBMarco Boscaro
Marco Boscaro
Luciana BordinLuciana Bordin
Luciana Bordin
CSChiara Sabbadin
Chiara Sabbadin
Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.

1 March 2001 in The Lancet
Verified
Journal Article
Closed access
MBMarco Boscaro
Marco Boscaro
Luisa BarzonLuisa Barzon
Luisa Barzon
FFFrancesco Fallo
Francesco Fallo
NSNicoletta Sonino
Nicoletta Sonino